AT
Avalo Therapeutics Inc
🇺🇸XNAS.AVTXUnited StatesHealthcare
$16.33USDup +0.27 (+1.68%)OpenDelayed3:24 PM
Price$16.33+0.27 (+1.68%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US05338F3064
- CUSIP
- 05338F207
Company
- Employees
- 33
- Headquarters
- Wayne, United States
- Website
- https://www.avalotx.com
- CEO
- Dr. Garry A. Neil M.D.
Market
- Shares outstanding
- 53.6M
- Market cap
- $875.78M
Key dates
- Next earnings
- Nov 5, 2026
Highlights
- Market cap
- $861.3M
- EPS LTM
- -$2.30
- P/E LTM
- -8.64
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $59K-86.62%down year on year
- Net income
- -$100.33M-117.1%down year on year
- Gross margin
- -16,888.14%-380.37%down year on year
- Free cash flow
- -$66.38M-39.98%down year on year
Other listings
This company is not listed on any other exchange we cover.
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.